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IvermectinPeritoneal macrophages were isolated from wild type (WT) mice and from mice invalidated for the P2X7
receptor (KO) which had been pretreated with thioglycolate. In cells fromWT mice, 1 mM ATP increased the
intracellular concentration of calcium ([Ca2+]i), the uptake of ethidium bromide, the production of reactive
oxygen species (ROS), the secretion of IL-1β, the release of oleic acid and of lactate dehydrogenase; it
decreased the intracellular concentration of potassium ([K+]i). In KO mice, ATP transiently increased the
[Ca2+]i conﬁrming that the P2X7 receptor is a major receptor of peritoneal macrophages. WKYMVm, an
agonist of receptors for formylated peptides (FPR) also increased the [Ca2+]i in murine macrophages. The
slight increase of the [Ca2+]i was strongly potentiated by ivermectin conﬁrming the expression of functional
P2X4 receptors by murine peritoneal macrophages. CRAMP, the unique antimicrobial peptide derived from
cathelin in mouse inhibited all the responses coupled to P2X7 receptors in macrophages from WT mice.
Agonists for FPR had no effect on the increase of the [Ca2+]i in response to ATP. CRAMP had no effect on the
increase of the [Ca2+]i evoked by a combination of ATP and ivermectin in macrophages from P2X7-KO mice.
In summary CRAMP inhibits the responses secondary to the activation of the murine P2X7 receptors
expressed by peritoneal macrophages. This inhibition is not mediated by FPR receptors and is speciﬁc since
CRAMP has no effect on the response coupled to P2X4 receptors. It can thus be concluded that the interaction
between P2X7 receptors and cathelin-derived antimicrobial peptides is species-speciﬁc, in some cases (man)
positive in others (mouse) negative.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Cathelicidins are proteins related to the cationic host defense
peptides and contribute to the primary, innate phase of immunity [1].; ATR-FTIR, attenuated total
SA, bovine serum albumin;
A, 2′,7′-dichlorodihydroﬂuor-
hyl ether)-N,N,N',N'-tetraacetic
ylated peptides; HEPES, N-[2-
O mice, knockout mice; ROS,
from the Fonds National de la
y grant BFU/2007-62728/BMC
cher of the Fonds National de la
postdoctoral grant from the
elgique, M. Vandenbranden is
ntiﬁque and U. Fontanils by a
ll rights reserved.They are expressed by macrophages, lymphocytes, epithelial cells,
keratinocytes, cells lining the upper respiratory tree, vaginal cells.
Their conserved N-terminal domain shares analogies with cathelin,
an inhibitor of cathepsin L. Consensus sequences for proteases are
present in the central domain of these proteins. The sequence of the
C-terminal domain varies according to species from 12 to more than
100 residues [2]. After their release in the extracellular medium,
cathelicidins are digested by elastase or proteinase 3 or kallikrein
and their C-terminal domain which is a peptide with bactericidal
properties is released [3]. LL-37 is the sole human orthologue of these
peptides and is derived from an 18-kDa precursor [4]. Its unusually
high content of basic and hydrophobic residues accounts for its ability
to form an amphipathic alpha helix [5]. LL-37 interacts with the
negative charges surrounding bacteria through the positively charged
side of the helix. In a second step the hydrophobic residues of the
peptide affect the structure and the integrity of the membrane of the
bacteria, a process which eventually kills them. These bactericidal
properties of LL-37 are very sensitive to the ionic composition of the
medium specially the concentration of cations. In media with an ionic
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LL-37 required to observe a bactericidal effect are so high that the
bactericidal activity in vivo has been questioned [6]. LL-37 has many
other effects [7]. It is chemotactic for macrophages, neutrophils and
polymorphonuclear leukocytes and it promotes the degranulation of
mast cells [8], it accelerates wound healing [9] and increases
angiogenesis [10]. It also neutralizes LPS activity [11]. These
pleiotropic responses involve various receptors such as Toll like
receptors [12], epidermal growth factor receptor [13] or receptors for
formylated peptides (FPR) [14]. Recently Mookherjee et al. [15]
reported that the immunomodulatory functions of LL-37 were
mediated by an intracellular receptor, the glyceraldehyde 3-phos-
phate dehydrogenase (GPDH). More relevant to the present work,
Elssner et al [16] showed that LL-37 could increase the release of IL-
1β from human macrophages. This response was blocked by
antagonists of the P2X7 receptor suggesting that LL-37 could activate
this purinergic receptor in macrophages. The afﬁnity of the P2X7
receptor for ATP is very low (in the millimolar range) and it is very
unlikely that after its diffusion in the extracellular medium such high
concentrations of the nucleotide reach the P2X7 receptor expressed in
the plasma membrane of a neighbor cell. Considering that low
concentrations of LL-37 could stimulate this receptor, it was
suggested that the P2X7 receptor was more a receptor for anti-
microbial peptides than for adenine nucleotides. At the opposite with
this general view, Mookherjee et al. [15] have reported that inhibitors
of P2X7 receptors had no effect on the secretion of MCP-1 from
monocytes stimulated by LL-37. We have previously reported that LL-
37 inhibited the P2X7 receptor expressed by mouse submandibular
glands [17]. Since this result could be explained either by a species
(man versus mouse) or a tissue (macrophage versus exocrine gland)
difference, we decided to reevaluate the response of murine
macrophages to CRAMP, the unique cathelicidin expressed by mice
[18]. Our results show that CRAMP inhibits the responses coupled to
P2X7 receptors (calcium uptake, potassium release, formation of
reactive oxygen species (ROS), release of oleic acid, secretion of IL-1β,
uptake of ethidium bromide and release of LDH) without affecting the
variation of the [Ca2+]i in response to the activation of P2X4
receptors. The mouse P2X7 receptor is thus the target of CRAMP,
the murine antimicrobial cathelicidin-related peptide. The interaction
between CRAMP and the purinergic receptor provokes the inhibition,
not the activation of the receptor. It is thus concluded that, at least in
mouse, the cathelicidin-related peptide is not the natural agonist of
P2X7 receptors.
2. Materials and methods
2.1. Materials
Ethylene glycol-bis-(β-aminoethyl ether)-N,N,N',N'-tetraacetic
acid (EGTA), N-[2-hydroxyethyl] piperazine-N'-[2-ethanesulfonic
acid] (HEPES), ivermectin, adenosine 5′-triphosphate disodium salt
(ATP), fetal bovine serum (FBS), lipopolysaccharide from E. coli (LPS,
Sigma catalog ref. 2880), β-NADH, sodium pyruvate and formylated
Met-Leu-Phe (fMLF) were obtained from Sigma-Aldrich (St. Louis,
MO). Bovine serum albumin (BSA) fraction V was from Roche
Diagnostics (Mannheim, Germany). Trishydroxymethylamino-
methane (TRIS) was from VWR (Leuven, Belgium). GLLRKGGEKI-
GEKLKKIGQKIKNFFQKLVPQPEQ (CRAMP), LESIFRSLLFRVM (MMK-1),
Try-Lys-Tyr-Met-Val-D-Met-NH2 (WKYMVm) and KRIVQ-
RIKDFLRNLVPRTES (KR-20) were custom synthesized with 99% purity
by GL Biochem (Shanghai, China). 9,10-[3H]oleic acid was purchased
from American Radiolabeled Chemicals Inc. (St. Louis, MO). The
scintillation solution Ecoscint A was from National Diagnostics
(Atlanta, GA). The 2′,7′-dichlorodihydroﬂuorescein diacetate (DCFH-
DA), fura2-AM, ethidium bromide, PBFI-AM, the glutamine-free
amino acids mixture, phosphate-buffered saline (PBS), RPMI-1640,Hanks' balanced salt solution (HBSS), L-glutamine and the solution
of penicillin–streptomycin were from Invitrogen (Groningen, The
Netherlands). Thioglycollate was from Becton-Dickinson (Franklin
Lanes, NJ). The polyclonal anti-mouse IL-1β antibody was from R&D
Systems (Minneapolis, MN). The biotinylated monoclonal anti-mouse
IL-1β antibody and the mouse IL-1β were from Endogen (Perbio
Science, Erembodegem, Belgium). The HRP substrate 1 Step Ultra
TMB-ELISA and the peroxidase-linked streptavidin were from Pierce
(Perbio Science, Erembodegem, Belgium).
The experiments were carried out on C57Bl/6J P2X7R+/+ wild-
type mice (WT) and P2X7R−/− null mice (KO) kindly supplied by
Pﬁzer Inc. (Groton, CT). Breeding of P2X7 knockout mice males with
females was used to maintain the colony of receptor-deﬁcient
animals. Mice used in the experiments were between 20 and 25 g.
The expression of P2X7 receptors in wild-type mice and its absence in
null mice was tested by Western blot as previously described [19].
2.2. Cell culture
Adult maleWT or KOmice (25 g) were used for these experiments.
Peritoneal macrophages were prepared according to McCarron et al.
[20]. Brieﬂy, peritoneal exsudates were induced by injection of 1.5 ml
thioglycollate solution (4% in sterile water) 3 or 4 days before
harvesting the cells. The animals were fasted overnight and sacriﬁced
by rising the CO2 concentration in accordance with the procedures of
the Belgian Ministry of Agriculture under the supervision of the
institutional ethical committee (protocol no. 221N). Ten milliliters of
sterile phosphate-buffered saline (PBS) without calcium or magne-
sium (pH 7.2) containing 10 U/ml heparin were injected in the
peritoneal cavity. The abdomen was gently massaged after its
distension. The ﬂuid was recovered and transferred to a sterile tube
kept on ice. After centrifugation at 1500 g for 10 min at 4 °C, the
cellular pellet was resuspended in RPMI 1640 medium supplemented
with 20 mM HEPES, 10% fetal bovine serum (FBS), 2 mM L-glutamine,
100 U/ml penicillin and 100 μg/ml streptomycin (RPMImedium). Ten
million cells were added to culture ﬂasks (usually two ﬂasks per
mouse) and incubated at 37 °C for at least 2 h in a humidiﬁed
atmosphere containing 5% CO2. Nonadherent cells and the medium
were then aspirated and replaced with 10 ml fresh RPMImedium. The
cells were incubated overnight at 37 °C in the presence of 250 ng/mL
LPS before use.
2.3. Determination of the [Ca2+]i
The culture plates were washed twice with 10 ml PBS. The cells
were gently scraped off the plates with a rubber policeman. Theywere
incubated at 25 °C for at least 1 h in a HEPES-buffered medium (HBM)
containing (mM): 24.5 HEPES (pH 7.4), 96 NaCl, 6 KCl, 2.5 NaH2PO4,
11.5 glucose, 5 sodium pyruvate, 5 sodium glutamate, 5 sodium
fumarate. Thismediumalso contained 1mMCaCl2 andMgCl2, 1% (v/v)
glutamine-free amino acids mixture, 1% (w/v) BSA (medium HBT) in
the presence of 3 μM fura2-AM. At the end of this incubation the cells
were washed and diluted with HBM supplemented with 1 mM CaCl2.
They were transferred in the cuvette of a ﬂuorimeter and maintained
at 25 °C under constant stirring. The light emitted at 510 nm was
measured after excitation at 340 and 390 nm. At the end of the
incubation, the cells were permeabilized with 100 μM digitonin and
the autoﬂuorescence of the samples was estimated by quenching of
fura2 with 100 mM manganese. The blank values were subtracted
from the results and the [Ca2+]i was estimated as described by
Grynkiewicz et al. [21].
2.4. Determination of the [K+]i
Macrophages were incubated at 25 °C for at least 1 h in HBT in the
presence of 3 μMPBFI-AM. At the end of this incubation, the cells were
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transferred in the cuvette of a ﬂuorimeter and maintained at 25 °C
under constant stirring. The light emitted at 490 nm (slitwidth 16 nm)
wasmeasured after excitation at 345 nm (slitwidth 16 nm). Before the
beginning of each measurement the voltage was adjusted to get a
signal corresponding to 10% of the maximal signal. Results have been
plotted as arbitrary ﬂuorescence units (a.f.u.) without any attempt to
calibrate the traces.
2.5. Assay of the formation of a pore
The cells were washed twice with 10 ml PBS and gently scraped
off the plate with a rubber policeman. The formation of the pore was
measured with the ﬂuorescent dye ethidium bromide [22]. Macro-
phages from two mice were diluted with 3 ml HBT and for each
assay, a 1-ml aliquot was washed and diluted with 2 ml HBM.
Ethidium bromide was added at a ﬁnal concentration of 20 μM. The
cells were allowed to equilibrate for 5 min before the beginning of
the measurement which was performed at 37 °C under constant
stirring. The samples were excited at 360 nm and the light emitted
at 580 nm was measured every second. At the end of the
measurement, the maximum uptake was estimated by adding
100 μM digitonin and the results were calculated taking this value
as reference.
2.6. Assay of the production of ROS
The production of ROS was estimated with 2′,7′-dihydrodichloro-
ﬂuorescein (DCFH) which becomes ﬂuorescent after oxidation
to 2′,7′-dichloroﬂuorescein (DCF) by hydrogen peroxide, peroxyl
radical or peroxynitrite anion [23]. Aliquots (1 ml) of the cellular
suspension were preincubated in the dark, at 25 °C for at least 1 h in
HBT in the presence of 6 μM DCFH-DA, a cell-permeant analog of
DCFH. After this incubation, 0.5 ml of the cellular suspension were
washed once with NaCl 0.9% and the cellular pellet was resuspended
in 2 ml HBM with 1 mM calcium. The assay was performed at 25 °C
under constant stirring in the cuvette of a ﬂuorimeter. The samples
were excited at 485 nm and the light emitted at 525 nm was
measured every second.
2.7. Assay of IL-1β secretion
Peritoneal macrophages from one mouse were resuspended in
RPMI medium and plated at 500,000 cells/ml in 12-well plates. After
3 h at 37 °C, the medium was removed and the cells were incubated
overnight in fresh RPMI medium containing 250 ng/ml LPS. The
cells were washed twice with PBS. They were then incubated for
15 min at 37 °C in 1 ml Hanks' balanced salt solution (HBSS)
without magnesium but containing 1 mM CaCl2, 0.1% BSA and the
tested agent. Each condition was tested in duplicates. Incubation
medium was collected and centrifuged at 10,000 g for 5 min to
remove detached cells. The IL-1β content was assayed by sandwich
ELISA. A 96-well plate was coated overnight with 1 μg/ml polyclonal
anti-mouse IL-1β antibody and blocked with 4% BSA in PBS for 1 h at
room temperature. The wells were washed twice with Tris–Tween
buffer (Tris–HCl 50 mM, pH 7.5 and 0.2% Tween-20). Aliquots of
medium samples or recombinant IL-1β standards were diluted to
150 μl with HBSS containing 1 mM CaCl2 and 0.1% BSA and mixed
with 150 μL biotinylated monoclonal anti-mouse IL-1β antibody
(0.4 μg/ml solution). One hundred microliters of this mix was added
in duplicate to the wells. Each assay was performed in duplicates.
The plate was incubated at 37 °C for 2 h and then washed four
times. The captured immune complexes were incubated for 30 min
at room temperature with 100 μL streptavidin-HRP (0.2 μg/mL),
washed four times and colorimetrically developed with 100 μL HRP
substrate. After the addition of 100 μL stop solution (H2SO4 1.8 M),the absorbance was read at 450 nm in a Synergy HT plate reader
(Bio-Tek, Winooski, VT).
2.8. Assay of the release of oleic acid
Peritoneal macrophages from three mice were diluted with RPMI
medium and plated. After 3 h at 37 °C, the medium was removed
and the cells were incubated overnight in RPMI medium containing
0.5 μCi/ml [3H]oleic acid. The medium was removed and the cells
were washed twice with 10 ml PBS. They were then incubated for 1
h at room temperature in RPMI medium. After two washes with PBS,
the cells were incubated in 1 ml HBM supplemented with 0.1% BSA,
the amino acid mixture and 1 mM CaCl2 and the tested agent for
20 min at 37 °C. Each assay was performed in triplicate. At the end
of the incubation, 600 μl of the supernatant were centrifuged for
5 min at 10,000 g to remove detached cells and 500 μl were
transferred to scintillation vials. The radioactivity was estimated in a
TriCarb liquid scintillation analyzer (Perkin Elmer, Waltham, MA)
after the addition of 5 ml Ecoscint A (National Diagnostics, Atlanta,
GA).
2.9. Assay of the release of LDH
Macrophages were resuspended in HBM medium supplemented
with 0.1% BSA, 1% (v/v) glutamine-free amino acids and 1 mM CaCl2,
in the absence of magnesium. They were incubated at 37 °C under
constant agitation either in control or in the tested condition. Each
condition was tested in triplicate. At the end of the incubation the
cellular suspension was centrifuged for 5 min at 10,000×g. To
estimate the amount of LDH present in the medium at the beginning
of the incubation (blank values), a similar procedure was applied to
non-incubated aliquots of cells. Aliquots of cells were also sonicated to
estimate the total LDH activity. The assay was performed in a 96-well
microplate. Ten microliters of the enzyme solution (cellular superna-
tant) were transferred to the wells. Then, 190 μl of Tris–EGTA–NADH
(56 mM Tris, pH 7.4, 5.6 mM EGTA and 170 μM β-NADH) and 20 μl of
14mM pyruvate were added to the wells. The disappearance of NADH
was monitored at 340 nm for 20 min at 30 °C (Synergy HT, BioTek).
Absorbance measurements were performed at time intervals of 45 s,
the absorbance decreasing linearly with time. The change of
absorbance per minute was calculated by linear regression and
the blank value was subtracted from the results obtained with the
incubated cells.
2.10. Determination of the secondary structure of CRAMP using
attenuated total reﬂection–Fourier transform infrared
spectra (ATR-FTIR)
KR-20 was dissolved in 2 mM HEPES and CRAMP in DMSO at a
5 mg/ml concentration. Just before measurement, 2 μl CRAMP
were deposited on a 0.025-μm pore size dialysis disc (Millipore
VSWP02500) ﬂoating on 2 mM HEPES buffer solution (pH 7.4). After
10 min, the dialyzed sample was transferred to the ATR reﬂect.
The infrared spectra were obtained and analyzed as described in ref.
[24]. Brieﬂy 1 μl of the peptide solution (KR-20 or dialyzed CRAMP)
were uniformally spread on a diamond internal reﬂection element.
The samples were evaporated under a stream of nitrogen. The
spectra were obtained on a Bruker IFS55 FTIR spectrophotometer
(Bruker, Ettlingen, Germany) equipped with a MCT detector
(broadband 120,000–420 cm−1, liquid nitrogen cooled) at a
resolution of 2 cm−1 and were subtracted for residual water vapor
spectral contribution to the signal. The amide hydrogen/deuterium
exchange was performed as described by Vigano et al. [25]. Brieﬂy
the sample was ﬂushed with nitrogen gas saturated with D2O by
bubbling through a series of four vials containing D2O. Exchange was
monitored by the decrease of the amide II peak area around
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the amide I peak area (1600–1700 cm−1 region) taken as a
reference. The spectra obtained after deuteration were analyzed by
Fourier self-deconvolution as previously described [25].
2.11. Statistical analysis
Results were analyzed with the Mann–Whitney non-parametric
test. ⁎⁎⁎Pb0.001; ⁎⁎Pb0.01; ⁎Pb0.05.
3. Results
3.1. Effect of CRAMP on the variation of the [Ca2+]i in response to
extracellular ATP
The murine peritoneal macrophages were detached from the
culture plate and loaded with fura2. The [Ca2+]i was measured in the
presence of 1 mM calcium but in the absence of extracellular
magnesium. As shown in Fig. 1, the [Ca2+]i was rather stable when
the macrophages were incubated in control conditions at 25 °C. The
addition of 1 mM ATP sharply increased the [Ca2+]i (from 97±8 nM
to 486±54 nMwithin 10 s) which nearly doubled for the next 3 min.
By itself CRAMP (1–10 μM concentration range) did not signiﬁcantly
affect the [Ca2+]i. The peptide dose-dependently inhibited the late
response to extracellular ATP (from 733±75 nM without CRAMP
down to 336±39 nM with CRAMP 3 min after the addition of ATP)
without affecting the rapid increase of the [Ca2+]i (486±54 nM
without CRAMP versus 494±50 nM with CRAMP 10 s after the
addition of ATP). The variation of the [Ca2+]i 30 s before and 1 minFig. 1. Effect of CRAMP on the increase of the [Ca2+]i in murine peritoneal macrophages
exposed to ATP. Peritoneal macrophages loaded with fura2 were incubated at 25 °C in a
medium containing 1 mM CaCl2 in control conditions. At 2 min various concentrations
of CRAMP were added to the medium. At 7 min the cells were exposed to 1 mM ATP.
Results are expressed as the [Ca2+]i and are the means±S.E.M. of n experiments. For
the clarity of the graph only one out of every 10 points has been plotted. Insert: The
variation of the [Ca2+]i 30 s before and 1min after the addition of 1mMATPwas plotted
as a function of the concentration of CRAMP.after the addition of ATP to the medium was plotted as a function of
the concentration of CRAMP (Fig. 1). The half maximal inhibitory
concentration of CRAMP ranged between 300 nM and 1 μM. These
results suggested that CRAMP inhibited one of the purinergic
receptors expressed by macrophages.
3.2. Interaction between CRAMP and the ATP-gated cation channel
In the next experiments the effect of the peptide on the uptake
of extracellular calcium was tested (Fig. 2, lower panel). Calcium (1
mM) was added to the medium of cells preincubated in the
presence of EGTA. In control cells calcium provoked a rapid and
transient increase of the [Ca2+]i. In cells stimulated with 1 mM ATP
the addition of calcium to the medium provoked a more substantial
initial increase of the [Ca2+]i followed by a sustained increase for
the next 5 min. CRAMP had no effect on the basal uptake of calcium,
but in the presence of 1 mM ATP it inhibited part of the initial
increase and fully suppressed the sustained uptake in response to
the nucleotide. These results suggested that ATP activated a P2X
receptor coupled to a calcium channel which remained open for
several minutes and which was blocked by CRAMP. Among P2X
receptors macrophages mostly express P2X4 and P2X7 receptors
[26]. To determine which of these receptors was regulated byFig. 2. Effect of CRAMP on the uptake of extracellular calcium in response to 1 mM ATP.
Peritoneal macrophages loaded with fura2 were incubated at 25 °C in the absence
(upper panel) or in the presence (lower panel) of 3 μM CRAMP, in the absence of
extracellular calcium. Two minutes after the beginning of the assay, 100 μM EGTA was
added to the medium followed 30 s later by 1 mM ATP. At 3 min calcium was added to
the medium at a ﬁnal 1 mM concentration. Results are the means±S.E.M. of n
experiments.
Fig. 3. Effect of CRAMP on the variation of the [Ca2+]i in macrophages from P2X7-KO
mice in response to ATP. Peritoneal macrophages from P2X7-KOmice were incubated at
25 °C in the presence of 1 mM CaCl2; in the absence (circles) or in the presence of 3 μM
ivermectin (triangles). Two minutes after the beginning of the assay CRAMP was added
to the medium at a 3-μM ﬁnal concentration (closed symbols). Three minutes later the
cells were stimulated with 10 μM ATP. The results are the means±S.E.M. of n
experiments.
Fig. 4. Effect of CRAMP on the variation of the [K+]i in response to ATP. Peritoneal
macrophages loaded with PBFI were incubated at 25 °C in the presence of 1 mM
CaCl2. Two minutes after the beginning of the assay CRAMP was added to the medium at
a 3-μM ﬁnal concentration (lower panel). Three minutes later some cells were stimulated
with 1 mM ATP (triangles). Results are the means±S.E.M. of n experiments.
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from P2X7-KO mice. We have previously conﬁrmed that these mice
do not express P2X7 receptors [19]. As shown in the upper panel of
Fig. 3, a low concentration of ATP (10 μM) provoked a slight and
transient increase of the [Ca2+]i in the macrophages from P2X7-KO
mice. Ivermectin is a macrolide which potentiates the responses
coupled to the P2X4 receptor by blocking its internalization on one
hand and by its interaction with an allosteric site on the other hand
[27]. When cells were preincubated with ivermectin, the variation
of the [Ca2+]i in response to ATP was increased and prolonged
(Fig. 3, upper panel). CRAMP had no effect on the response of
macrophages from P2X7-KO mice either to ATP alone or to ATP plus
ivermectin suggesting that it did not block the channel coupled to
P2X4 receptors (Fig. 3, lower panel). The activation of P2X7
receptors increases the permeability not only to calcium but also
to potassium. Macrophages were loaded with PBFI which is a
ﬂuorescent dye sensitive to the concentration of potassium. The
ﬂuorescence did not vary in macrophages incubated in controlconditions at 25 °C (Fig. 4). The addition of 1 mM ATP to the
medium provoked a steady decrease of the signal. This drop
disappeared when macrophages were incubated in the presence
of a high (90 mM) concentration of potassium. CRAMP had, by
itself, no effect on the ﬂuorescence of PBFI conﬁrming that it did not
open the non-selective cation channel. The decrease of the
ﬂuorescence of PBFI in response to ATP was inhibited in cells
incubated in the presence of 3 μM CRAMP. From these results it can
be concluded that CRAMP inhibited the non-selective cation channel
coupled to P2X7 receptors.
3.3. Effect of agonists for FPR on the response to ATP
Cathelin-derived peptides activate receptors for chemotactic
formylated peptides [14]. Considering that murine macrophages
express some classes of these receptors [28], the inhibition exerted
by CRAMP on the non-selective channel coupled to P2X7 receptors
might be secondary to its activation of chemotactic receptors. To test
this hypothesis the interaction between ATP and other agonists of
FPRs was examined. As shown in Fig. 5, 1 μM fMLF (a speciﬁc agonist
for FPR) and 10 μMMMK-1 (a speciﬁc agonist for formylated peptide
receptor like-1, FPRL1/FPR2) had by themselves no effect on the
[Ca2+]i; 10 μM WKYMVm (a speciﬁc agonist for formylated peptide
receptor like-2, FPRL2/FPR3) transiently doubled the [Ca2+]i (from
Fig. 5. Effect of agonists of formylated peptide receptors (FPR) on the variation of the
[Ca2+]i in response to ATP. Peritoneal macrophages loaded with fura2 were incubated
at 25 °C in the presence of 1 mMCaCl2. Twominutes after the start of the assay, the cells
were exposed to an agonist of a receptor for formylated peptides (FPRA). Threeminutes
later 1 mM ATP was added to the medium. Results are the means±S.E.M. of n
experiments.
Fig. 6. Effect of CRAMP on the uptake of ethidium bromide in response to ATP.
Peritoneal macrophages were incubated at 37 °C in the presence of ethidium bromide
and in the absence of extracellular calcium. Two minutes after the start of the assay
3 μM CRAMP was added to the medium (lower panel) or the cells were maintained in
control conditions (upper panel). Five minutes later some cells were exposed to 1 mM
ATP (squares) and the other cells were incubated in control conditions (triangles). The
results are expressed as the percentage of maximal uptake of ethidium bromide and are
the means±S.E.M. of n experiments. For the clarity of the graph only 1 out of every 15
points were plotted.
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affected by a preincubation with 3 μM CRAMP (from 80±11 nM to
236±17 nM, n=3, data not shown). fMLF, MMK-1 and WKYMVm
did not affect the increase of the [Ca2+]i in response to 1 mM ATP.
From these results it can be concluded that the inhibition of the
response to ATP by CRAMP is not reproduced by speciﬁc agonists of
FPR or FPRL receptors. Our data also suggest that CRAMP is not an
inhibitor of the receptors activated by WKYMVm.
3.4. Effect of CRAMP on the formation of a pore in response to ATP
The sustained activation of the P2X7 receptor eventually
provokes the formation of a pore permeant to large ions like
ethidium. Once inside the cell, the salt interacts with double-strand
nucleic acids and becomes ﬂuorescent [22]. As shown in the upper
panel of Fig. 6, the ﬂuorescence emitted by ethidium bromide
slightly increased with time in macrophages incubated in control
conditions. The slope of the curve was increased about 3-fold by the
addition of ATP to the medium. In the next experiments the cells
were exposed to 3 μM CRAMP before the addition of 1 mM ATP. The
peptide had no effect by itself on the uptake of ethidium bromide
but nearly fully blocked the response to ATP (Fig. 6, lower panel).
The prolonged activation of P2X7 receptors provokes the release of
LDH. The incubations of macrophages with 1 mM ATP for 30 min
at 37 °C increased the relase of LDH from 19±1.5% (n=11) to42.2±2.2% (n=10). By itself 3 μM CRAMP did not affect the release
of LDH (20.4±1.8%, n=10) but the peptide inhibited the effect of
1 mM ATP (30.8±3.9%, n=6, Pb0.05 when compared to ATP
alone). These results suggested that CRAMP inhibited not only
the non-speciﬁc cation channel coupled to P2X7 receptors but
also the formation of a pore by these receptors and the subsequent
cell death.
3.5. Effect of CRAMP on the release of oleic acid provoked by
extracellular ATP
Purinergic agonists increase the release of oleic acid from
peritoneal macrophages: this response is probably secondary to
their activation of various phospholipases [29]. As shown in Fig. 7,
1 mM ATP increased the release of oleic acid from macrophages
labelled with [3H]oleic acid (from 6.8±0.6% during a 20-min
incubation at 25 °C to 12.8±0.8% after a 20-min incubation in the
presence of ATP, n=9). By itself CRAMP had no effect on the basal
release of oleic acid (6.8±0.8% and 6.0±0.7% in the presence of 1
and 3 μM CRAMP). The peptide inhibited the response to extracel-
lular ATP: the nucleotide only increased the release of [3H]oleic acid
to 8.4±0.8% and 8.5±1.0% (n=9) in the presence of respectively 1
and 3 μM CRAMP.
Fig. 7. Effect of CRAMP on the release of [3H]oleic in response to ATP. Murine peritoneal
macrophages were prelabelled with [3H]oleic acid andwashed as described inMaterials
and methods. The cells were incubated for 20 min in control conditions or in the
presence of 1 mM ATP, 1 or 3 μM CRAMP or in the combined presence of ATP and
CRAMP. The results are expressed as the percentage of the total radioactivity
incorporated in the cells and are the means±S.E.M. of 11 (control and 3 μM CRAMP)
or 4 experiments (1 μM CRAMP). ⁎Pb0.05, ⁎⁎Pb0.01, ⁎⁎⁎Pb0.001.
Fig. 8. Effect of CRAMP on the production of ROS in response to ATP. Peritoneal
macrophages loaded with DCF were incubated at 25 °C in the presence of 1 mM CaCl2.
Two minutes after the start of the assay 3 μM CRAMP was added to the medium (lower
panel) or the cells were maintained in control conditions (upper panel). Five minutes
later some cells were exposed to 1 mM ATP (squares) and the other cells were
incubated in control conditions (triangles). The results are expressed as arbitrary
ﬂuorescence units (a.f.u.) and are the means±S.E.M. of n experiments.
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extracellular ATP
The production and the release of ROS is a major response of
macrophages to extracellular ATP [30]. As shown in Fig. 8, the
ﬂuorescence of DCF was stable in macrophages incubated either in
control conditions (upper panel) or in the presence of 3 μM CRAMP
(lower panel). This result suggested that the ﬂuorescent probe
remained in a reduced form when the cells were maintained in
basal conditions. The addition of ATP to themedium provoked a linear
increase of the ﬂuorescence of DCF (+6364±1191 a.f.u. (n=10)
after a 3-min exposure to ATP) secondary to its oxidation by the ROS
produced in response to ATP. A preincubation with 3 μM CRAMP
strongly inhibited the response to ATP (+3320±415 a.f.u. after a
3-min exposure to ATP, n=9, Pb0.01 when compared to the
ﬂuorescence in the presence of ATP alone).
3.7. Effect of CRAMP on the secretion of IL-1β in response to
extracellular ATP
P2X7 receptors trigger caspase-1 activation and IL-1β secretion
from peritoneal macrophages. After a 20-min incubation with 1 mM
ATP the concentration of IL-1β in the medium increased from
411±81 pg /mL (n=5) to 2634±434 pg/mL (n=10). CRAMP
(3 μM) did not modify the basal release of IL-1β (552±130 pg/mL).
CRAMP inhibited the secretion of IL-1β in response to extracellular ATP
(1594±195 pg/mL, n=5, Pb0.05 when compared to ATP alone).
3.8. Secondary structure of CRAMP
In a ﬁnal experiment we examined the secondary structure of
CRAMP using ATR-FTIR spectroscopy. These measurements were
performed with 5 μg CRAMP or KR-20, the peptide containing the 20
last residues of LL-37 [31]. The spectra of the two peptides were
compared with the spectra of myoglobin, as a reference for a
predominently α-helical structure, and avidin, as a β-sheet reference
structure . As shown in Fig. 9, the spectrum of myoglobin showed two
major quasi-symmetrical peaks in the 1500–1800 cm−1 range. The
peak centered at 1655 cm−1 is the amide I signal. The second band at
1545 cm−1 is the amide II signal. In the spectrum of avidin a ﬁrst peakat 1630 cm−1 was observed (Fig. 9A, peak 1) This peak had a shoulder
around 1650 cm−1. A second peak for avidin was centered around
1530 cm−1 (Fig. 9A, peak 2). The spectrum of KR-20 was very similar
to the spectrum of myoglobin with two symmetrical peaks at 1656
and 1545 cm−1, suggesting that the peptide had an α-helicoidal
secondary structure in aqueous medium. The spectrum of CRAMPwas
also mostly in favor of an α-helix structure except that the amide I
signal was not symmetrical: it had a tail around 1640 cm−1 suggesting
a slight β-sheet component and a shoulder around 1675 cm−1
probably due to a turn (Fig. 9). These initial results led us to suspect
that both CRAMP and KR-20 formed predominently an α-helix in our
experimental conditions. In a next step the two peptides were
deuterated after ﬂushing with nitrogen gas saturated with D2O.
Deuteration is generally used to eliminate a possible contribution of
random coil structure (which is very sensitive to deuteration) to the
very close alpha helical spectral region (which is less sensitive to
deuteration). Deuteration ampliﬁed the asymmetry of the amide I
peak and an analysis of the deuterated curve revealed the major peak
near 1652 cm−1 and also twominor peaks centered at 1674 cm−1 and
1630 cm−1. The amide II peak for both peptides decreased with time
(about −20% after 15 min for KR-20 and −40% for CRAMP). In the
same time a peak around 1440 cm−1 increased. These results
Fig. 9. Infrared-ATR spectra of KR-20 and CRAMP. Upper panel: The spectra of KR-20 (K)
and CRAMP (C) were compared to the spectra of avidin (A) and myoglobin (M). Middle
and lower panel: The spectra of KR-20 (middle panel) and of CRAMP (lower panel)
were measured before (C) or after (D) deuteration. The spectra after deuteration were
analyzed using Fourier self-deconvolution (A).
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helical structure while the secondary structure of CRAMP was
probably more complex but also formed at least partly an α-helix.
4. Discussion
In this work we show that CRAMP inhibits the sustained increase
of the [Ca2+]i, the decrease of the [K+]i, the uptake of ethidium
bromide, the release of LDH, IL-1β and of oleic acid and the production
of ROS elicited by extracellular ATP in murine peritoneal macro-
phages. Macrophages express both P2Y and P2X receptors but the
responses to extracellular ATP affected by CRAMP are all mediated by
P2X7 receptors [32], suggesting that CRAMP blocks the activation ofthese purinergic receptors. This is in part conﬁrmed by the experi-
ments performed with macrophages from P2X7-KO mice. In these
cells ATP only provoked a transient increase of the [Ca2+]i conﬁrming
that macrophages from KO mice did not express functional P2X7
receptors. The small increase of the [Ca2+]i was strongly potentiated
by ivermectin. This macrolide inhibits the desensitization of P2X4
receptors by blocking the internalization of the receptors [27]. CRAMP
had no effect on the increase of the [Ca2+]i provoked by a combination
of ATP and ivermectin, conﬁrming that CRAMP did not interact with
the signalling pathway coupled to P2X4 receptors. The selectivity of
the effect of CRAMP on P2X7 receptors but not on P2X4 receptors
excludes a non-speciﬁc effect of CRAMP on the plasma membrane.
LL-37 and CRAMP have been shown to chemoattract neutrophils, T
lymphocytes, monocytes or macrophages after binding to FPRL-1/
FPR2 [28]. In murine peritoneal macrophages fMLF, an agonist of FPR
[14] and MMK-1, a speciﬁc agonist of FPRL-1/FPR2 [33] did not
increase the [Ca2+]i. WKYMVm, a speciﬁc agonist for FPRL-2/FPR3
[34], transiently doubled the [Ca2+]i. This is consistent with the
current view that murine macrophages occasionally express FPRL-2/
FPR3 [35]. CRAMP had no effect on this response to WKYMVm
suggesting that it does not interact with FPRL-2/FPR3. None of the
three agonists of the FPR reproduced the inhibition exerted by CRAMP
on the increase of the [Ca2+]i elicited by ATP. These results suggest
that FPR do not mediate the inhibition exerted by CRAMP on P2X7
receptors.
This inhibition was unexpected considering that in human
macrophages LL-37 mimicked the response to extracellular ATP and
increased the secretion of IL-1β. Antagonists of the P2X7 receptor
blocked this response, and it was concluded that the P2X7 receptor
was activated when human macrophages were incubated in the
presence of LL-37 [16]. Several models have been proposed to explain
this activation of P2X7 receptors by LL-37. It was initially suggested
that LL-37 might increase the permeability of the plasma membrane
and provoke the release of intracellular ATP which could have some
autocrine effects [16]. LL-37 itself might interact with the extracellular
loop of the receptor or with its C-terminal domain after entering the
cell [36]. This last hypothesis was recently excluded by Tomasinsig et
al. who reported that LL-37 could interact even with a P2X7 receptor
lacking the intracellular C-terminal domain [37]. These authors also
observed that the capacity to stimulate P2X7 receptors varied among
cathelicidin-derived peptides. The LL-37 from orangutan and from
gibbon which, like the human LL-37, can form an α-helix not only in
organic medium but also in aqueous solutions, stimulated the P2X7
receptors. The LL-37 frommacaque or from leaf monkey which have a
lower structuring capacity did not interact with the P2X7 receptors.
These results led Tomasinsig et al. to conclude that the ability of
antimicrobial peptides to react with P2X7 receptors was related to
their ability to form an amphipathic α-helix in aqueous solution [37].
LL-37 and CRAMP share major structural properties: they lack
cysteine residues and are small cationic peptides with a net positive
charge of 6 for both peptides and a high content of hydrophobic
residues (35% for LL-37 and 29% for CRAMP). They also share the
capacity to form an amphipatic α-helix in organic solvents. Using
ATR-FTIR spectroscopy we have studied the secondary structure of
CRAMP and of the C-terminal eicosapeptide of LL-37, KR-20 (this
peptide contains most of the alpha-helical structure of LL-37) [38].
These peptides were dissolved in a 2 mMHEPES buffer (pH 7.4). It has
been demonstrated that ATR-FTIR can provide important information
on the secondary structure of a protein and on its modiﬁcations after
interaction with a ligand, a lipid or another protein [24]. These
informations can be obtained by the analysis of the amide I peak
(corresponding to the C=O vibration) and the amide II peak
(corresponding to the N–H deformation). These peaks are observed
at different wavelengths when present in a random coil structure, or
in anα-helix, or in a β-sheet. The spectra of the two peptides revealed
that the amide I and II peaks were centered at wavelengths
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deuterium in the N–H group is also related to the relative content of
secondary structures in the protein: this exchange is very slow in a
well-structured region of a protein or a peptide. The height of the
amide I and II peaks in the presence of D2O vapor can thus be used as
an index of the relative structural compactness of the protein. The
decrease of these peaks was rather small suggesting that the two
peptides had well-deﬁned secondary structures rather than random
structures. Deuteration modiﬁed the shape of the amide I peak and
exacerbated the shoulders observed around 1630 and 1670 cm−1,
especially for CRAMP. From these results we can conclude that KR-20
formsmostly anα-helix in an aqueous buffer. The structure of CRAMP
seems more complex combining both some α-helix and a turn. The
presence of two prolyl residues in the C-terminal region of CRAMP
(positions 30 and 32) might account for this turn. Our results are at
variancewith the previous observations of Yu et al. [39]. Using circular
dichroism analysis and NMR spectroscopy these authors reported that
in aqueous solutions CRAMP adopted a random coil structure but that
it formed an α-helix in membrane mimetics environments. The
discrepancy between their results and ours might be explained by the
fact that peptides with different primary structures were used in the
two studies. There is 85% similarity between the two peptides. We
used a peptide with 34 amino acids. Its sequence has been reported by
Pestonjamasp et al. [40], and it corresponds to the peptide registered
as CRAMP in the database for antimicrobial peptides (access number
AP00281) [41]. The peptide used by Yu et al. has 38 amino acids: it
lacks the C-terminal Q but has a pentapeptide extension (ISRLA) at the
N-terminus. The peptide of Yu et al. has also an extra positive charge
at neutral pH (+7) and has a higher proportion of hydrophobic
residues (34%). Ten of these hydrophobic residues are located on the
same side of a potential α-helix in their peptide and only six residues
have a similar position in our CRAMP. These differences in the primary
structure of the two peptides might account for their distinct
conformations in water. Thus both LL-37 and CRAMP can form an
α-helix in aqueous buffer and interact with P2X7 receptors but LL-37
is an agonist on P2X7 receptors fromman and CRAMP is an antagonist
on murine P2X7 receptors. The two peptides have a different index of
binding potential: 2.99 kcal/mol for LL-37 and only 1.74 kcal/mol for
CRAMP [41]. This difference in energy could account for the ability of
LL-37 to switch the receptor in an active conformation. However this
hypothesis cannot explain why LL-37 blocked the responses coupled
to P2X7 receptors in mouse submandibular glands [17]. The best
explanation for these results would be that not only the peptides but
also the receptors themselves contribute to the difference in the
interaction between antimicrobial peptides and P2X7 receptors.
Mouse and man P2X7 receptors share 80% homology but they diverge
with respect to their sensitivity towards agonists (specially benzoyl-
ATP) or antagonists (specially isoquinolone derivatives) [42]. It is thus
reasonable to conceive that P2X7 receptors frommouse andman have
different responses to antimicrobial peptides.
In conclusion our results with the mouse model (CRAMP and
murine macrophages) conﬁrm that the antimicrobial peptide and the
receptor can interact but clearly establish that this interaction is not
always positive and that antimicrobial peptides are thus not universal
agonists of P2X7 receptors.
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